Frontiers in Oncology (Oct 2022)

Cerebral glucose changes after chemotherapy and their relation to long-term cognitive complaints and fatigue

  • Gwen Schroyen,
  • Gwen Schroyen,
  • Gwen Schroyen,
  • Georg Schramm,
  • Georg Schramm,
  • Donatienne Van Weehaeghe,
  • Donatienne Van Weehaeghe,
  • Donatienne Van Weehaeghe,
  • Nicolas Leenaerts,
  • Nicolas Leenaerts,
  • Nicolas Leenaerts,
  • Nicolas Leenaerts,
  • Thomas Vande Casteele,
  • Thomas Vande Casteele,
  • Thomas Vande Casteele,
  • Thomas Vande Casteele,
  • Jeroen Blommaert,
  • Jeroen Blommaert,
  • Jeroen Blommaert,
  • Michel Koole,
  • Michel Koole,
  • Michel Koole,
  • Ann Smeets,
  • Ann Smeets,
  • Ann Smeets,
  • Koen Van Laere,
  • Koen Van Laere,
  • Koen Van Laere,
  • Koen Van Laere,
  • Stefan Sunaert,
  • Stefan Sunaert,
  • Stefan Sunaert,
  • Sabine Deprez,
  • Sabine Deprez,
  • Sabine Deprez

DOI
https://doi.org/10.3389/fonc.2022.1021615
Journal volume & issue
Vol. 12

Abstract

Read online

PurposeTo investigate the short-term cerebral metabolic effects of intravenous chemotherapy and their association with long-term fatigue/cognitive complaints.Experimental designUsing [18F]-FDG-PET/CT whole-body scans, we retrospectively quantified relative cerebral glucose metabolism before and after neoadjuvant chemotherapy in a cohort of patients treated for non-metastatic breast cancer (2009-2019). Self-report of cognitive complaints and fatigue were prospectively assessed 7 ± 3 years after therapy. Metabolic changes were estimated with i) robust mixed-effects modelling in regions-of-interest (frontal, parietal, temporal, occipital, and insular cortex) and ii) general-linear modelling of whole-brain voxel-wise outcomes. iii) The association between metabolic changes and self-reported outcomes was evaluated using linear regression-analysis.ResultsOf the 667 screened patients, 263 underwent PET/CT before and after chemotherapy and 183 (48 ± 9 years) met the inclusion criteria. After chemotherapy, decreased frontal and increased parietal and insular metabolism were observed (|ß|>0.273, pFDR<0.008). Separately, additional increased occipital metabolism after epiribucin+ cyclophosphamide (EC) and temporal metabolism after EC+ fluorouracil chemotherapy were observed (ß>0.244, pFDR≤0.048). Voxel-based analysis (pcluster-FWE<0.001) showed decreased metabolism in the paracingulate gyrus (-3.2 ± 3.9%) and putamen (3.1 ± 4.1%) and increased metabolism in the lateral cortex (L=2.9 ± 3.1%) and pericentral gyri (3.0 ± 4.4%). Except for the central sulcus, the same regions showed changes in EC, but not in FEC patients. Of the 97 self-reported responders, 23% and 27% experienced extreme fatigue and long-term cognitive complaints, respectively, which were not associated with metabolic changes.ConclusionBoth hyper- and hypometabolism were observed after chemotherapy for breast cancer. Combined with earlier findings, this study could support inflammatory mechanisms resulting in relative hypermetabolism, mainly in the parietal/occipital cortices. As early metabolic changes did not precede long-term complaints, further research is necessary to identify vulnerable patients.

Keywords